Company News: Novartis

Share this article:
At a meeting this week, Novartis said it plans to submit cancer compounds Tasigna, for initial therapy in patients with chronic myeloid leukemia (CML), and Zometa, for patients with breast cancer, to the FDA by year's end. Novartis could make several other oncology submissions next year, including one for kidney cancer drug Afinitor, pending the outcome of ongoing clinical trials. In results of one trial, unveiled a day before the meeting, Novartis said Tasigna showed improvement over Gleevec among early-stage leukemia patients. Tasigna is already marketed for the minority of CML patients who are resistant to Gleevec, which is set to lose patent protection starting in 2015. "We have a productive and innovative pipeline that holds promise for many patients," said Joe Jimenez, CEO of the Novartis Pharmaceuticals Division.
 

Share this article:

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.